Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 40 of the 54 sources its claims cite were checked for support.
Abstract
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to months. A notable recent discovery shows that ketamine, a N -methyl- d -aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants. Basic studies show that ketamine rapidly induces synaptogenesis and reverses the synaptic deficits caused by chronic stress. These findings highlight the central importance of homeostatic control of mood circuit connections and form the basis of a synaptogenic hypothesis of depression and treatment response.
Overview
CoChat Summary
TL;DR
The paper proposes a synaptogenic hypothesis of depression: stress and depression cause synaptic loss and neuronal atrophy in mood-related circuits, while rapid-acting ketamine reverses these deficits through glutamate burst, BDNF, mTOR, and synaptogenesis. It contrasts slow typical antidepressants with ketamine and highlights new therapeutic targets.
Key findings
- Depression is associated with decreased volume of cortical and limbic regions such as the prefrontal cortex (PFC) and hippocampus, and postmortem studies report decreased synapse number in the dorsolateral PFC, reduced pyramidal neuron size but not number, decreased GABAergic interneurons and glia, and altered GABA/glutamate cycling.
- Chronic stress in rodents reduces apical dendrite length and branching and decreases spine synapse number and function in layer V pyramidal neurons of the medial PFC; atrophy is observed after as little as 1 week of restraint stress (20 to 30 min per day), and chronic stress also decreases adult hippocampal neurogenesis and medial PFC glia.
- Ketamine produces rapid antidepressant responses within hours in treatment-resistant depressed patients, with effects sustained for 7 to 10 days; in rodents it rapidly induces synaptogenesis, reverses spine density deficits and anhedonia/anxiety caused by 3 weeks of chronic stress, and requires mTOR signaling, BDNF, Arc, and GSK3 inhibition.
- Typical antidepressants such as SSRIs take weeks to months to produce therapeutic response and leave more than one-third of depressed individuals resistant; they increase neurotrophic factor expression and plasticity slowly, whereas ketamine more profoundly affects fast excitatory glutamate transmission, BDNF release, and synaptogenesis.
Methods
- Review/perspective article synthesizing basic and clinical literature; no new primary data are reported.
- Evidence reviewed includes human brain-imaging and postmortem MDD studies, rodent chronic stress models (e.g., chronic unpredictable stress, restraint stress), and pharmacological studies of typical antidepressants and ketamine.
- Narrative synthesis comparing mechanisms of typical antidepressants and ketamine and proposing a synaptogenic hypothesis; no systematic review or meta-analysis is described.
Limitations
- Stated in the paper: MDD neurobiology remains poorly understood due to lack of biomarkers, relatively low heritability, and heterogeneity of precipitating factors; imaging provides connectivity information but not the integrity and efficiency of connections; postmortem neuronal morphology studies are hampered by poor fixation and tissue condition; preclinical interpretation is limited by available animal models, and additional human imaging is needed to confirm ketamine circuitry.
- Stated in the paper: ketamine’s psychotomimetic effects and abuse potential limit its development and use; clinical response to NR2B selective agents does not appear as rapid as ketamine, and further studies are needed; many molecular alterations in depression cannot always be distinguished from medication status because studies are not always sufficiently powered.
- Evident from the text: as a review, it does not provide a systematic search strategy, quality assessment, or primary quantitative synthesis; many mechanistic conclusions rely on rodent models and correlational human postmortem/imaging findings.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
27 Valid · 0 Not valid · 4 Not checked · 6 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Studies of neuronal morphology in human postmortem brain tissue have been hampered by poor fixation and tissue condition, but we recently reported that the number of synapses, determined by electron microscopy, is decreased in the dlPFC of depressed patients (16).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Neuronal Atrophy and Synaptic Loss in Depression
What the sources say
- Supportedcites [16] Kang HJ Nat. Med 2012 18 1413 22885997 PMC3491115 source
The paper reports a marked decrease in spine synapse number in the dorsolateral prefrontal cortex of subjects with major depressive disorder compared with controls. Its Electronic Microscopic Stereology methods describe counting those synapses in postmortem tissue using electron micrographs. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A notable recent discovery shows that ketamine, a N-methyl-D-aspartate receptor antagonist, produces rapid (within hours) antidepressant responses in patients who are resistant to typical antidepressants.”
- Also stated in: § Abstract · boosted
“Recent studies report what is arguably the most important discovery in half a century: the therapeutic agent ketamine that produces rapid (within hours) antidepressant actions in treatment-resistant depressed patients (4, 5).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Abstract
What the sources say
- Not checked — no full text of the sourcecites [4] Berman RM Biol. Psychiatry 2000 47 351 10686270 source
- Supportedcites [5] Zarate CA Jr Arch. Gen. Psychiatry 2006 63 856 16894061 source
The Comment section reports a robust antidepressant response to ketamine within hours in treatment-resistant subjects, with improvement over placebo significant from 110 minutes on clinician ratings and 40 minutes on self-ratings. It also identifies ketamine as an NMDA antagonist. Page numbers are not provided in the supplied passages. (LLM, conf=0.94)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Abstract · boosted
Every source the paper cites for this claim was checked and supports it.
In the paper
“Chronic unpredictable stress (CUS), a putative model of depression, results in behavioral abnormalities, including core symptoms of depression such as anhedonia (7).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Stress Causes Neuronal Atrophy and Decreases Synaptic Density
What the sources say
- Supportedcites [7] Li N Biol. Psychol 2011 69 754 source
The Conclusions describe CUS as a paradigm that results in anhedonia, a core symptom of depression. The Results report that CUS-exposed rats showed reduced sucrose preference, indicating anhedonia, and increased latency to feed in a novel environment, indicating another behavioral abnormality. (LLM, conf=0.94)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We have found that infusion of rapamycin into the medial PFC, but not the dorsal striatum, blocks the effects of systemic ketamine administration (6).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Partly supportedcites [6] Li N Science 2010 329 959 20724638 PMC3116441 sourceExperimental — accuracy not yet measured
The passage on behavioral tests (labeled Abstract; Fig. 3D–F) reports that local rapamycin infusion into the medial PFC completely blocked ketamine’s effects in the forced swim and novelty-suppressed feeding tests. Our copy does not report a dorsal-striatum infusion or establish that it failed to block those effects, so the regional comparison is unsupported. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In addition, the synaptogenic actions of ketamine are blocked in mice with a knock-in of the BDNF Met allele that impairs BDNF mRNA transport to dendrites, as well as in conditional BDNF mutant mice (32, 49).”
§ Synaptic Dysfunction in Depression: Potential Therapeutic Targets > Rapid-Acting Antidepressants Increase Synaptogenesis
What the sources say
- Not matchedcites [32] Liu R Biol. Psychol 2012 71 996
Its entry has no title and year that we can search by.
- Partly supportedcites [49] Autry AE Nature 2011 475 91 21677641 PMC3172695 sourceExperimental — accuracy not yet measured
The Abstract (page not provided) reports that ketamine did not produce antidepressant-like behavioural effects in inducible BDNF knockout mice. It does not report that ketamine’s synaptogenic effects were blocked in those mice, or describe BDNF Met knock-in mice or impaired dendritic mRNA transport. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Not matched
14 more claims · 10 with their cited sources checked
Create a free account to see all 37 claims and every source verdict.
- It may state two separate claims as one. 17
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“While synaptic plasticity is a well-known key mechanism in learning and memory (Dayan and Cohen, 2011;Kandel, 2001), unequivocal studies suggest that dysfunction of synaptic plasticity with neuronal atrophy and cell death contribute to the pathophysiology of depression and therapeutic response could be associated with overcoming this deficit (Duman and Aghajanian, 2012;Krystal et al., 2013;Shakesb”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, synaptic dysfunctions with neuronal atrophy and reductions of glial and GABAergic interneurons in the dorsolateral prefrontal cortex (dlPFC) are found in post-mortem analyses of brains of depressive patients (and animal models of chronic unpredictable stress; Duman and Aghajanian, 2012; Underwood et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Duman and Aghajanian, 2012
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Broadly, positive valence system deficits are linked primarily to altered dopaminergic and/or opioid signaling within midbrain striatal circuits 94,101 , but may intersect with plasticity impairments and dysconnectivity of excitatory glutamatergic synapses in an overlapping prefrontal-mesolimbic circuit 5 to produce the full spectrum of affective biases seen in depression.”
From Neuroplasticity in cognitive and psychological mechanisms of depression: an integrative model (2020) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Such complex effects seem to ultimately result in increased neurogenesis and synaptogenesis, improved neuroplasticity, and normalization of stress-related neurodegeneration [77,78].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postmortem findings from these animal models consistently demostrate that stress induces synaptic dysfunction [5,6,135], including reductions in synaptic density, as measured by both quantification of synaptic structure and assessments of synaptic protein expression”
From Challenges and rewards of in vivo synaptic density imaging, and its application to the study of depression (2025) · cites this paper as [6]
Experimental — accuracy not yet measured
16 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.617 · Cited by 12,052
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881
Self-citationNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926
Neurocircuitry of Mood Disorders
Price, J. L., & Drevets, W. C. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.104 · Cited by 1,606
Research works printed but not linked: 1
- 10.1016/j.pbb.2011.09.010 · DOI · Paper page
Cited by
Items 801–900 of 1,640
Zhao, J., Zhang, M., Zhang, H., Wang, Y., Chen, B., & Shao, J. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110843 · Cited by 20
“The disruption and atrophy of neurons and glia in PFC has been proven to be caused by depression (Duman and Aghajanian, 2012).”
BackgroundBrain-derived neurotrophic factor: a biomarker for obsessive-compulsive disorder?
Oliveira-Maia, A. J., & Castro-Rodrigues, P. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00134 · Cited by 18
“…and BDNF also seems to be required for the antidepressant actions of fluoxetine on synaptic transmission, long-term potentiation, ocular dominance plasticity and extinction training plasticity (Maya Vetencourt et al., 2008; Karpova et al., 2011; Bath et al., 2012; Duman and Aghajanian, 2012).”
BackgroundPérez‐Domper, P., Gradari, S., & Trejo, J. L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.06.001 · Cited by 22
Zhou, Q., Dong, J., Xu, T., & Cai, X. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.08.025 · Cited by 16
“…target of rapamycin (mTOR) phosphorylation, which contributes to increased local dendritic translation of proteins that are essential for synaptic remodeling and dendritic spine synthesis (Li et al., 2010; Duman and Aghajanian, 2012; Costa-Mattioli and Monteggia, 2013; Martinowich et al., 2013).”
Sha, Z., & Banihashemi, L. (2020) · Psychological Medicine · doi:10.1017/s0033291720002676 · Cited by 17
“…that lower levels of synaptic signalling related genes in MDD tightly involved in a reduction of neural plasticity and number of synapses in both dlPFC and hippocampus (Duman & Aghajanian, 2012; Duric et al., 2013; Kang et al., 2012), which was associated with lower volumes in these regions.”
BackgroundLim, S.-H., Shin, S., Kim, M., Kim, E. C., Lee, D. Y., Moon, J., Park, H.-Y., Ryu, Y., Kang, Y.-M., Kang, Y. J., et al. (2020) · Journal of Cell Science · doi:10.1242/jcs.243972 · Cited by 15
Asthana, N., Mehaffey, E., & Sewell, D. D. (2021) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2021.05.026 · Cited by 20
“Moreover, these neurobiological changes have been shown to be associated with core symptoms of depression.(49) One possible mechanism by which stress may induce neuronal atrophy in the mPFC is through the activation of innate immune receptors including Tolllike receptors 2 and 4, which, in turn, induce”
Funayama, Y., Li, H., Ishimori, E., Kawatake-Kuno, A., Inaba, H., Yamagata, H., Seki, T., Nakagawa, S., Watanabe, Y., Murai, T., et al. (2022) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2021.12.009 · Cited by 19
Carboni, E., & Carta, A. R. (2022) · Journal of Integrative Neuroscience · doi:10.31083/j.jin2105144 · Cited by 17
Sterley, T.-L., Howells, F. M., Dimatelis, J. J., & Russell, V. A. (2015) · Metabolic Brain Disease · doi:10.1007/s11011-015-9742-5 · Cited by 16
“…to both SHR and SD. Reduced neuronal cell adhesion molecule 1 in WKY hippocampus may indicate reduced synaptic plasticity (Doherty et al., 1995, Rønn et al., 2000) and decreased number of synaptic connections, which is consistent with WKY as a model of depression (Duman and Aghajanian, 2012).”
ResultFlores, G., Ibáñez-Sandoval, O., Gómez, A. B. S., Camacho‐Abrego, I., Moreno, A. R., & Morales‐Medina, J. C. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.11.047 · Cited by 18
“In this regard, most of the targets of antidepressant binding in the brain are structures in the limbic system such as the prefrontal cortex (PFC), septal nucleus, subiculum, and hippocampus (Kaulen et al., 1989; Duman and Aghajanian, 2012).”
BackgroundJing, L., Duan, T., Tian, M., Yuan, Q., Tan, J., Zhu, Y.-Y., Ding, Z.-Y., Cao, J., Yang, Y., Zhang, X., et al. (2015) · Scientific Reports · doi:10.1038/srep15000 · Cited by 14
Lee, A.-R., Ko, K. W., Lee, H., Yoon, Y.-S., Song, M., & Park, C. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.0541-16.2016 · Cited by 20
“…to studies on MDD and a rodent stress model, the size of the depression-related brain regions decreases and neuronal atrophy appears (reduction in the length and branching of apical dendrites) with reduced synapses (Rajkowska et al., 1999; Stockmeier et al., 2004; Duman and Aghajanian, 2012).”
BackgroundHCN channels in the hippocampus regulate active coping behavior
Fisher, D. W., Han, Y. S., Lyman, K. A., Heuermann, R. J., Bean, L. A., Ybarra, N., Foote, K. M., Dong, H., Nicholson, D. A., & Chetkovich, D. M. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14539 · Cited by 16
Chen, M., Jin, J., Bi, H., Zhang, Y., Sun, M., Li, X., & Wang, Y. (2025) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2025.104502 · Cited by 14
Nose‐to‐Brain Delivery of Chlorella vulgaris Extracellular Vesicles for Antidepressant Effects
Jin, K., Wang, R., Chen, B., Zhong, D., Cheng, S., Tong, A., Qi, Y., Lü, J., & Zhou, M. (2025) · Journal of Extracellular Vesicles · doi:10.1002/jev2.70198 · Cited by 19
Cheung, N. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1751605 · Cited by 33
Gao, Z.-Y., Chen, T.-Y., Yu, T.-T., Zhang, L.-P., Zhao, S.-J., Gu, X.-Y., Pan, Y., & Kong, L.-D. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00831-0 · Cited by 21
“Brain-derived neurotrophic factor (BDNF) expression in hippocampus of mice is increased by ketamine, its deletion in hippocampus attenuates antidepressant responses [25, 26].”
BackgroundUliana, D. L., Gomes, F. V., & Grace, A. A. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01333-1 · Cited by 15
“Also, a decreased hippocampal volume [11] and impaired blood flow in the medial prefrontal cortex (mPFC) [12] are observed in MDD. Deficits in the mPFC-HIP connectivity have also been observed in rodent models for depression based on stress exposure [13].”
BackgroundLu, S., Ge, Q., Yang, M., Zhuang, Y., Xu, X., Niu, F., Liu, B., & Tian, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116419 · Cited by 18
Liu, C., Zhao, Y., & Zhao, W. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10123-z · Cited by 17
“Depression is characterized by pathological changes such as neuronal atrophy and synaptic inhibition in the PFC, as evidenced by studies (Abdallah et al. 2015; Duman et al. 2016; Duman and Aghajanian 2012).”
Chen, C.-Y., Wang, Y., Lei, L., & Zhang, Y. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111186 · Cited by 16
Potassium channels in depression: emerging roles and potential targets
Zhang, J., Zhu, Y., Zhang, M., Yan, J., Zheng, Y., Yao, L., Li, Z., Shao, Z., & Chen, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01319-0 · Cited by 15
Brain Network Dynamics and Multiscale Modeling of Neurodegenerative Disorders: A Review
Shaheen, H., & Melnik, R. (2025) · IEEE Access · doi:10.1109/access.2025.3542634 · Cited by 25
Reduced striatal dopamine DA D2 receptor function in dominant-negative GSK-3 transgenic mice
Gómez‐Sintes, R., Bortolozzi, A. A., Artigas, F., & Lucas, J. J. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2014.07.004 · Cited by 15
“Also, the different cellular roles of GSK-3 suggest an association with neuroplasticity mechanisms evoked by antidepressant drugs (Duman and Aghajanian, 2012).”
Noto, B., Klempin, F., Alenina, N. V., Bäder, M., Fink, H., & Sander, S. E. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.09.051 · Cited by 17
Recovery of Chronic Stress-Triggered Changes of Hippocampal Glutamatergic Transmission
Lin, M. T., Hou, G., Zhao, Y. H., & Yuan, T. (2018) · Neural Plasticity · doi:10.1155/2018/9360203 · Cited by 19
Cognitive dysfunction in mice lacking proper glucocorticoid receptor dimerization
Looveren, K. V., Boxelaere, M. V., Callaerts‐Vegh, Z., & Libert, C. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226753 · Cited by 15
“Centrally, chronic elevation of the stress response will affect neuronal functioning by inhibiting neurogenesis, proper synaptic pruning and changes in neurotransmitter systems [5, 6], and induce a wide range of behavioral changes including cognitive processes.”
BackgroundGisabella, B., Babu, J., Valeri, J., Rexrode, L., & Pantazopoulos, H. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.646678 · Cited by 19
“…et al., 2009; Feyissa et al., 2009; Sweet et al., 2009; Kristiansen et al., 2010; Schmitt et al., 2010; Vrajova et al., 2010; Penzes et al., 2011; Duman and Aghajanian, 2012; Kang et al., 2012; Duric et al., 2013; Glausier and Lewis, 2013; Licznerski and Duman, 2013; Konopaske et al., 2014,…”
BackgroundZeng, P. H., Wang, X., Ye, C., Su, H.-F., Fang, Y., Zhang, T., & Tian, Q. (2021) · Aging · doi:10.18632/aging.203072 · Cited by 20
“In the PFC and hippocampus of chronic stress exposed animals, the neuronal atrophy and loss were also found, which related to the reduction in the volume of these brain regions [38].”
BackgroundFilipović, D., Novak, B., Xiao, J., Yan, Y., Bernardi, R. E., & Turck, C. W. (2023) · Journal of Proteomics · doi:10.1016/j.jprot.2023.104925 · Cited by 14
Zeitler, S., Schumacher, F., Monti, J., Anni, D., Guhathakurta, D., Kleuser, B., Friedland, K., Fejtová, A., Kornhuber, J., & Rhein, C. (2020) · Cells · doi:10.3390/cells9112502 · Cited by 15
“ASM and TRPC6 are both proteins that have implications at nerve termini and synapses, and the pathology of MDD is highly related to synaptic function [60].”
BackgroundNing, L., Zhou, Y., Chen, J., Hu, Z., Jiang, W., Guo, L., Xu, Y. H., Li, H., Xu, F., & Deng, D. (2022) · BMC Immunology · doi:10.1186/s12865-022-00479-3 · Cited by 15
“Since modern drugs with selective serotonin reuptake inhibitor (SSRI), based on the monoamine neurotransmitter hypothesis, have shown only 50–60% efficacy in a large number of clinical studies [7, 8].”
BackgroundNmda Receptor Antagonists for Depression: Critical Considerations
Serafini, G., Gonda, X., Rihmer, Z., Pompili, M., Girardi, P., Nasrallah, H. A., & Amore, M. (2015) · Annals of Clinical Psychiatry · doi:10.1177/104012371502700308 · Cited by 16
“15 Interestingly, Autry et al 16 suggested that ketamine-medi-ated antagonism of NMDAR at rest deactivates eukaryotic elongation factor 2 (eEF2) kinase (also called CaMKIII), inducing a reduced eEF2 phosphorylation and de-suppression of BDNF translation.”
The Physiological Function of nNOS-Associated CAPON Proteins and the Roles of CAPON in Diseases
Xie, W., Xing, N., Qu, J., Liu, D., & Pang, Q. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115808 · Cited by 12
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
“In contrast, fast-acting antidepressants work by enhancing structural plasticity, helping to restore the synaptic connections damaged by chronic stress [139].”
Age-dependent brain morphometry in Major Depressive disorder
Myoraku, A., Lang, A., Taylor, C. T., Mackin, R. S., Meyerhoff, D. J., Mueller, S. G., Strigo, I. A., & Tosun, D. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102924 · Cited by 15
“, 2009) and might be a reflection of age effects modulated by MDD through other neurodegenerative mechanisms, including but not limited to neuroinflammation, proteinopathies, and synaptic dysfunction (Maes et al., 2011; Furtado and Katzman, 2015; Brites and Fernandes, 2015; Gatchel et al., 2017; Rial et al., 2016; Dum…”
BackgroundWang, X., Cheng, M., Su, Y., Zhang, C., & Meng, X. (2022) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac083 · Cited by 13
“Synaptic dysfunction has also been implicated in depression (Duman and Aghajanian, 2012).”
BackgroundInfluentialStress-Activated Protein Kinase JNK Modulates Depression-like Behaviors in Mice
Zhou, X., Yi, W., Zhi, Y., Yu, J., Lu, D., Luo, Z., Yuan, L., Chen, L., Xu, Z., & Xu, D. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03209-x · Cited by 15
“In addition, rodent studies have provided detailed evidence of reduced synaptic density, and cell loss in models of depression and stress [34].”
BackgroundRen, L., Zhang, H., Tao, W., Xue, W., Yin, C., Zou, Z., Guo, X., Shen, Q., Wang, W., Jiang, H., et al. (2023) · Neuropeptides · doi:10.1016/j.npep.2023.102350 · Cited by 14
“Growing evidence links the pathophysiology of depression to the disruption of hippocampal synaptic plasticity (Duman and Aghajanian, 2012; Normann et al., 2018).”
BackgroundNeuroprotective astroglial response to neural damage and its relevance to affective disorders
Miguel-Hidalgo, J. J. (2023) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2023.00054 · Cited by 16
Kaneko, N., Wada, M., Nakajima, S., Takano, M., Taniguchi, K., Honda, S., Mimura, M., & Noda, Y. (2024) · Cerebral Cortex · doi:10.1093/cercor/bhad515 · Cited by 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
“119,126 A 2019 study found that chronic stress eliminated postsynaptic dendritic spines in the PFC and reduced correlated multicellular ensemble activity in PFC projection neurons.”
BackgroundAsch, R. H., Abdallah, C. G., Carson, R. E., & Esterlis, I. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-01913-3 · Cited by 13
Tianeptine induces mTORC1 activation in rat hippocampal neurons under toxic conditions
Seo, M. K., McIntyre, R. S., Cho, H. Y., Lee, C. H., Park, S. W., Mansur, R. B., Kim, G.-M., Baek, J. H., Woo, Y. S., Lee, J. G., et al. (2016) · Psychopharmacology · doi:10.1007/s00213-016-4309-7 · Cited by 12
Novel rapid-acting antidepressants: molecular and cellular signaling mechanisms
Thomas, A. M., & Duman, R. S. (2017) · Neuronal Signaling · doi:10.1042/ns20170010 · Cited by 14
“Both BDNF release and mTORC1 activation, two of the necessary components of ketamine’s antidepressant effect, promote synaptogenesis [43].”
Self-citationHuang, C., & Chen, J. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.05.114 · Cited by 14
Ketamine Alters Electrophysiological Responses to Emotional Faces in Major Depressive Disorder
Lundin, N. B., Sepe-Forrest, L., Gilbert, J. R., Carver, F. W., Furey, M. L., Zarate, C. A., & Nugent, A. C. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.007 · Cited by 20
Botanas, C. J., Custodio, R. J. P., Kim, H. J., de la Peña, J. B., Sayson, L. V., Ortiz, D. M., Kim, M., Lee, H. J., Acharya, S., Kim, K., et al. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108619 · Cited by 14
Cabanu, S., Pilar-Cuéllar, F., Zubakina, P., Florensa-Zanuy, E., Senserrich, J., Newman‐Tancredi, A., & Adell, A. (2022) · Pharmaceuticals · doi:10.3390/ph15030337 · Cited by 16
Convergent molecular and structural neuroimaging signatures of first-episode depression
Chen, Y., Chen, Y., Zheng, R., Jiang, Y. B., Zhou, B., Xue, K., Li, S., Pang, J., Li, H., Zhang, Y., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.132 · Cited by 16
Wang, S., Tang, S., Huang, J., & Chen, H. (2022) · General Psychiatry · doi:10.1136/gpsych-2022-100922 · Cited by 15
“73 74 The direct injection of BDNF into the hippocampus resulted in an antidepressant effect.”
BackgroundFilipović, D., Costina, V., Findeisen, P., & Inta, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315351 · Cited by 16
“Its etiology is not yet fully elucidated, but several reports indicate synaptic and mitochondrial dysfunctions [1,2].”
BackgroundReddy, P. V., Talukdar, P. M., Subbanna, M., Bhargav, P. H., Arasappa, R., Venkatasubramanian, G., Muralidharan, K., & Debnath, M. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2023.21.2.313 · Cited by 14
Treat the brain and treat the periphery: toward a holistic approach to major depressive disorder
Zheng, X., Zhang, X., Wang, G., & Hao, H. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.03.015 · Cited by 14
Yan, A. L., Wei, M., Gong, A. G. W., Song, P., Lou, J.-S., Bi, C. W. C., Xu, S. L., Xiong, A., Dong, T. T.-X., & Tsim, K. W. K. (2017) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2017.00118 · Cited by 14
“However, anti-depressants targeted on regulating neurotransmitter levels are not able to exert an effect to all the patients, indicating the complex pathogenesis during depression (Pehrson and Sanchez, 2014; Duman and Aghajanian, 2015).”
BackgroundInflammation associated with chronic heart failure leads to enhanced susceptibility to depression
Su, J., Wang, J., Ma, Y., Li, Q., Yang, Y., Huang, L., Wang, H., Li, H., Wang, Z., Tong, J., et al. (2019) · FEBS Journal · doi:10.1111/febs.14839 · Cited by 15
Zhang, J., Zhang, Z., Zhang, J., Zheng, Z., Yao, Z., Qu, S., & Huang, Y. (2019) · Neural Plasticity · doi:10.1155/2019/7492306 · Cited by 16
Chaves, T. V., Wilffert, B., & Sanchez, Z. M. (2020) · The American Journal of Drug and Alcohol Abuse · doi:10.1080/00952990.2020.1769118 · Cited by 16
Transcriptomic analyses of humans and mice provide insights into depression
Li, H., 650223,中国, 中. 昆., Su, X., Zhang, L.-W., Zhang, C., Wang, L., Li, W., Yang, Y., Lv, L., Li, M., et al. (2020) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2020.174 · Cited by 19
Monteleone, M. C., Billi, S. C., Viale, L., Catoira, N. P., Frasch, A. C. C., & Brocco, M. A. (2020) · Journal of Affective Disorders Reports · doi:10.1016/j.jadr.2020.100003 · Cited by 14
Advances in neurotransmitter-mediated prefrontal circuitry in depression
Li, S., Gao, M., Mou, Z., Zhang, H., Wang, Y., & Zhang, Y. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111475 · Cited by 12
Induction of plasticity and metaplasticity using noninvasive brain stimulation
Bhattacharya, A., Darmani, G., Udupa, K., Nankoo, J.-F., Ding, M. Y. R., & Chen, R. (2025) · Trends in Neurosciences · doi:10.1016/j.tins.2025.07.009 · Cited by 14
Kikutani, K., Hosokawa, K., Giga, H., Ota, K., Matsumata, M., Zhu, M., Takemoto, H., Ji, B., Ohshimo, S., Shime, N., et al. (2022) · Shock · doi:10.1097/shk.0000000000002030 · Cited by 14
“Synaptic dysfunction has been implicated in the pathophysiology underlying psychiatric and neurodegenerative disorders with cognitive impairment (27,28).”
BackgroundRegulation of dendritic spines in the amygdala following sleep deprivation
Rexrode, L., Tennin, M., Babu, J., Young, C., Bollavarapu, R., Lawson, L. A., Valeri, J., Pantazopoulos, H., & Gisabella, B. (2023) · Frontiers in Sleep · doi:10.3389/frsle.2023.1145203 · Cited by 16
“Interestingly, altered numbers of dendritic spines, which serve as morphological representations of encoded memory, are also consistently reported across several psychiatric disorders (DorphPetersen et al., 2009; Sweet et al., 2009; Penzes et al., 2011; Duman and Aghajanian, 2012; Glausier and Lewis, 2013; Licznerski…”
BackgroundZhang, Y., Pan, Y., Zheng, W.-Y., Li, H.-Y., Zhu, M., yang, W.-J. O., Qian, Y., Turecki, G., Mechawar, N., & Zhu, X. (2023) · Redox Biology · doi:10.1016/j.redox.2023.103005 · Cited by 15
“Both impaired serotonergic [34,35] and imbalanced glutamatergic neurotransmission and decreased synaptic plasticity have been associated with depression, especially in mPFC where DRN sero-tonergic neurons are heavily innervated [36,37].”
BackgroundSpanoudaki, M., Papadopoulou, S. Κ., Antasouras, G., Papadopoulos, K., Psara, E., Vorvolakos, T., Solovos, E., Chrysafi, M., Psallas, M., Mentzelou, M., et al. (2024) · Life · doi:10.3390/life14040479 · Cited by 20
“HPA axis seems to be dysregulated, leading to abnormal cortisol levels and stress responses [36].”
BackgroundZhang, Y., Wei, C., Wang, P., Zheng, L.-C., Cheng, Y., Ren, Z., Jin, Y., Yao, Y., & Liu, H. (2024) · Scientific Reports · doi:10.1038/s41598-024-76226-y · Cited by 20
Park, J. Y., Chae, S., Kim, C. S., Kim, Y. J., Yi, H. J., Han, E.-J., Joo, Y., Hong, S., Yun, J. W., Kim, H., et al. (2019) · Korean Journal of Physiology and Pharmacology · doi:10.4196/kjpp.2019.23.6.427 · Cited by 14
Neuroplasticity in dystonia: Motor symptoms and beyond
Quartarone, A., & Ghilardi, M. F. (2022) · Handbook of clinical neurology · doi:10.1016/b978-0-12-819410-2.00031-x · Cited by 16
Gawande, D. Y., Barewar, S., Taksande, J., Umekar, M. J., Ghule, B., Taksande, B. G., & Kotagale, N. R. (2022) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2022.06.001 · Cited by 14
Akiyama, S., Nagai, H., Oike, S., Horikawa, I., Shinohara, M., Lü, Y., Futamura, T., Shinohara, R., Kitaoka, S., & Furuyashiki, T. (2022) · Scientific Reports · doi:10.1038/s41598-022-15461-7 · Cited by 19
The contribution of gamma bursting to spontaneous gamma activity in schizophrenia
Spencer, K., Nakhnikian, A., Hirano, Y., & Levin, M. E. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1130897 · Cited by 13
“, 2003), increases plasticity in cortical circuits (e.g., Cornwell et al., 2012; Duman and Aghajanian, 2012), and increases SGA (e.”
BackgroundMolecular Mechanisms of Depression
Varidaki, A., Mohammad, H., & Coffey, E. T. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802456-0.00005-4 · Cited by 15
The protective role of Neuregulin1-ErbB4 signaling in a chronic social defeat stress model
Wang, W., Qiao, Y., Qu, H., Zhu, L., Mu, L., Li, C., Fang, J., & Lian, H. (2020) · Neuroreport · doi:10.1097/wnr.0000000000001464 · Cited by 13
Cheng, Y., Xu, J., Dong, C., Shen, Z., Zhou, C., Li, N., Lü, Y., Ran, L., Xu, L., Shan, B., et al. (2020) · NeuroImage Clinical · doi:10.1016/j.nicl.2020.102384 · Cited by 12
“These results suggest the potential of AnkG for mediating the effects of stress exposure to neurodysfunctions associated with depression (Duman and Aghajanian, 2012).”
BackgroundAlternatives to ketamine in depression: state-of-the-art and future perspectives
Jelen, L. A., King, S., & Stone, J. M. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317749456 · Cited by 12
de la Fuente Revenga, M., Zhu, B., Guevara, C. A., Naler, L. B., Saunders, J. M., Zhou, Z., Toneatti, R., Sierra, S., Wolstenholme, J. T., Beardsley, P. M., et al. (2021) · doi:10.1101/2021.02.24.432725 · Cited by 11
“05), extinction (n = 14-15 mice per group; extinction, F[3,104] = 20.”
The Effect of Ketamine on the Immune System in Patients with Treatment-Resistant Depression
Szałach, Ł. P., Ciesielska-Figlon, K., Daca, A., Cubała, W. J., & Lisowska, K. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157500 · Cited by 15
“This triggers intracellular signaling cascades involving brain-derived neurotrophic factor (BDNF) and the mechanistic target of rapamycin (mTOR), which promote synaptogenesis and restore synaptic connectivity in prefrontal and limbic regions implicated in depressive pathology [10,11].”
Yao, H., Wang, X., Chi, J., Chen, H., Liu, Y., Jiayi, Y., Yu, J., Ruan, Y., Xiang, X., Pi, J., et al. (2024) · Molecules · doi:10.3390/molecules29050964 · Cited by 12
Ketamine and its enantiomers for depression: a bibliometric analysis from 2000 to 2023
Zhao, L.-Y., Zhang, G.-F., Lou, X.-J., Hashimoto, K., & Yang, J. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01809-9 · Cited by 13
“Ronald S Duman (Yale University, USA) with only 59 academic articles, achieved an exceptionally high average citation rate of 170.54, reflecting the impact-ful nature of his work published in journals, including two articles in Science in 2010 and 2012 [34, 35].”
InfluentialMajor challenges in youth psychopathology: treatment-resistant depression. A narrative review
Menculini, G., Cinesi, G., Scopetta, F., Cardelli, M., Caramanico, G., Balducci, P. M., Giorgi, F. D., Moretti, P., & Tortorella, A. A. V. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1417977 · Cited by 20
“Other pathophysiological pathways targeted by treatment with ketamine include the modulation of prefrontal GABAergic neurons (132) and the stimulation of a - amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor (139, 140).”
BackgroundYang, C., Ali, T., Li, A., Gao, R., Yu, X., Li, S., & Li, T. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110156 · Cited by 11
Hu, L., Qiu, M., Fan, W., Wang, W.-E., Liu, S., Liu, X.-Q., Liu, S.-W., Shen, Z.-J., Zheng, Y., Liu, G., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1433026 · Cited by 13
“When juxtaposed with control mice, the cortical thickness at the S1FL region of the neocortex in DEX-treated mice was notably decreased by Nissl staining (Figure 2A-C), consistent with the decreased brain size (Figures 2D, E) often found in major depressive disorder (46).”
ResultKouba, B. R., & Rodrigues, A. L. S. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173899 · Cited by 15
Zhang, J., Duan, J., Li, W., Wang, X., Ren, S., Ye, L., Liu, F., Tian, X., Xie, Y., Huang, Y., et al. (2025) · Science Advances · doi:10.1126/sciadv.adq0444 · Cited by 14
“…that induced pyramidal cell disinhibition may activate downstream signaling, including phospho-mTOR, brain-derived neurotrophic factor, and glutamatergic AMPARs mediated excitatory transmission, which will help rees-tablish synaptic communication that is impaired in depression ( 63 , 64 ).”
M6A RNA epitranscriptome dynamics linked to major depressive disorder and suicide risk
Roy, B., & Dwivedi, Y. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-025-02165-5 · Cited by 18
“This fi nding not only highlights the regulatory role of m6A in shaping the transcriptomic landscape of the MDD brain [30] but also points to potential disruptions in neuronal communication and synaptic function in MDD [31].”
Ketamine Metabolomics in the Treatment of Major Depression
van Velzen, M., & Dahan, A. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000286 · Cited by 12
Theilmann, W., Alitalo, O., Yorke, I., & Rantamäki, T. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.11.018 · Cited by 14
“Activation of BDNF receptor TrkB and inhibition of GSK3β kinase have been associated with the mechanism of action of rapid-acting antidepressant ketamine [17,18].”
Xiu, J., Han, R., Liu, Z., Li, J., Liu, S., Shen, Y., Ding, Y., & Xu, Q. (2021) · Diabetes · doi:10.2337/db20-1030 · Cited by 16
Xu, H., Yu, Z.-H., Ge, M.-J., Shen, J., Han, F., Pan, C., Chen, J., Zhu, X.-L., Hou, W.-Y., Hou, Y.-Q., et al. (2021) · Hormones and Behavior · doi:10.1016/j.yhbeh.2021.105040 · Cited by 11
Subbanna, M., Talukdar, P. M., Abdul, F., Debnath, M., Reddy, P. V., Arasappa, R., Venkatasubramanian, G., Muralidharan, K., Gangadhar, B. N., Bhargav, P. H., et al. (2021) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2021.102876 · Cited by 13
Wang, H., Liang, L., Yang, C., Xiao, L., Wang, H., Wang, G., & Zhu, Z. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.11.018 · Cited by 12
Nass, S. R., Hahn, Y. K., Ohene‐Nyako, M., McLane, V. D., Damaj, M. I., Thacker, L. R., Knapp, P. E., & Hauser, K. F. (2023) · Viruses · doi:10.3390/v15030590 · Cited by 12
“Neuropsychiatric disorders are a major problem in persons infected with HIV (PWH), with the prevalence of self-reported depressive symptoms estimated to be around 40% [29–31], and two-fold higher rates of MDD compared to HIV-negative controls are reported in clinical studies [31].”
BackgroundInfluentialDong, B., Wang, J., Wang, M., Chen, Q., Kong, X., Chang, J., Li, X., Yue, T., & Wang, Y. (2023) · Talanta · doi:10.1016/j.talanta.2023.125272 · Cited by 9
Gai, Q., Chu, T., Li, Q., Guo, Y., Ma, H., Shi, Y., Che, K., Zhao, F., Dong, F., Li, Y., et al. (2024) · Human Brain Mapping · doi:10.1002/hbm.26670 · Cited by 11
Jakovcevski, M., Akbarian, S., & Benedetto, B. D. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.10.002 · Cited by 10
“Cell-type specificity, an underrepresented hallmark of epigenetics in MDD Histone modifications and their impairment in MDD Environmental challenges, such as stress exposure, can exaggerate or trigger most mood disorders and are considered to have a pivotal role in the pathogenesis of MDD.”
BackgroundInfluentialNeuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents
Waller, J. A., Nygaard, S., Li, Y., du Jardin, K. G., Tamm, J., Abdourahman, A., Elfving, B., Pehrson, A., Sánchez, C., & Wernersson, R. (2017) · BMC Neuroscience · doi:10.1186/s12868-017-0376-x · Cited by 11
Freitas, A. E., Heinrich, I. A., Moura, T. D. M., Fraga, D. B., Costa, A. P., Azevedo, D., Brocardo, P. S., Kaster, M. P., Leal, R. B., & Rodrigues, A. L. S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113398 · Cited by 13
Ketamine normalizes high-gamma power in the anterior cingulate cortex in a rat chronic pain model
Friesner, I. D., Martinez, E., Zhou, H., Gould, J. D., Li, A., Chen, Z. S., Zhang, Q., & Wang, J. (2020) · Molecular Brain · doi:10.1186/s13041-020-00670-w · Cited by 13
Metadata
- Authors
- Duman, R. S., & Aghajanian, G. K.
- Affiliations
- Yale University (US)
- Corresponding author
- Duman, Ronald S.
- ORCID
- Duman, Ronald S.
- Venue
- Science
- Published
- 2012-10-05
- Volume
- 338
- Issue
- 6103
- Pages
- 68-72
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4424898
- OpenAlex
- W2157504436
- Cited by
- 1,651
- References
- 57
- Citations by year
- 2026: 176 · 2025: 175 · 2024: 132 · 2023: 138 · 2022: 127 · 2021: 161 · 2020: 125 · 2019: 86 · 2018: 88 · 2017: 93 · 2016: 89 · 2015: 106 · 2014: 78 · 2013: 71 · 2012: 4
- FWCI
- 9.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH093897)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- depression, synaptic dysfunction, synaptogenesis, ketamine, NMDA receptor antagonists, antidepressant resistance, chronic stress, prefrontal cortex, hippocampus, mood regulation, rapid antidepressant response, therapeutic target
- MeSH terms
- Animals, Antidepressive Agents, Atrophy, Behavior, Major Depressive Disorder, Homeostasis, Humans, Neurons, Stress, Psychological, Synapses, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.